Carmat shareholders approved the terms of a €50m equity financing earlier this month. While the shares outstanding increased by 29.5%, we estimate funds on hand are sufficient to fund operations into H118, and likely through the completion of a pivotal study for the Carmat bioprosthetic heart. With the recent completion of the feasibility study, Carmat plans to start a CE mark enabling pivotal trial in H216, which could lead to commercialisation by H218. Our rNPV approach generates a val
05 May 2016
Setting the stage for pivotal heart study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Setting the stage for pivotal heart study
Carmat SA (ALCAR:PAR) | 0 0 0.7% | Mkt Cap: 195.7m
- Published:
05 May 2016 -
Author:
Pooya Hemami -
Pages:
8
Carmat shareholders approved the terms of a €50m equity financing earlier this month. While the shares outstanding increased by 29.5%, we estimate funds on hand are sufficient to fund operations into H118, and likely through the completion of a pivotal study for the Carmat bioprosthetic heart. With the recent completion of the feasibility study, Carmat plans to start a CE mark enabling pivotal trial in H216, which could lead to commercialisation by H218. Our rNPV approach generates a val